– May 1, 2009
May 1, 2009
View Issues
-
Tamoxifen Compliance
In a randomly selected population of post-menopausal breast cancer patients treated with either tamoxifen or anastrozole, discordance was found between self-reported adherence to prescribed treatment and actual records of prescription fills provided by local hospital and physician records. The findings support further research in developing strategies to better understand and overcome non-adherence. -
Adjuvant Imatinib for GIST
In a multicenter, randomized, placebo-controlled phase III trial, imatinib (400 mg/d) administered for one year was demonstrated to enhance progression-free survival for patients with gastrointestinal stromal tumors. This study was the basis for the FDA approval for such treatment in this setting. -
Time-to-Progression after Chemotherapy Increased in Unmutated IgVh CLL
Unmutated immunoglobulin variable heavy chain (IgVh) in patients with chronic lymphocytic leukemia is associated with worse outcome. -
Gefatinib (Iressa) as First-line Therapy for Advanced NSCLC in Patients with Poor Performance
In a phase II trial of gefitinib for patients with advanced NSCLC, demonstrable EGFR mutation, and poor performance status (PS 2-4), Inoue et al report a median survival of 17.8 months. -
Bisphosphonates and Breast Cancer: Good News and Bad News
Two recent reports relate to the expanded use of zoledronic acid or other bisphosphonate in current oncologic practice. -
Clinical Briefs in Primary Care Supplement
-
Pharmacology Watch
Aspirin dose and cardioprotection; uncovering modafinil's abuse potential; proton-pump inhibitors and clopidogrel; FDA actions.